CD160 and central nervous system cancer: To further explore the potential immune mechanism of MS4As in glioma, we analyzed correlations between MS4As with twenty-four immune inhibitory molecules, including ADORA2A, BTLA, CD160, CD244, CD274 (PDCD1LG1), CD96, CSF1R, CTLA4, HAVCR2, IDO1, IL10, IL10RB, KDR, KIR2DL1, KIR2DL3, LAG3, LGALS9, PDCD1, PDCD1LG2, NECTIN2, TGFB1, TGFBR1, TIGIT, and VTCN1 (Figure 10).